Agilent Q1 EPS Misses by 0.52% as Revenues Climb 7% to $1.8 B
Agilent reported Q1 fiscal 2026 EPS of $1.36, missing consensus by 0.52%, while revenues rose 7% to $1.8 billion, beating estimates by 0.27%. The company forecasts Q2 revenue of $1.79–1.82 billion (7–9% growth) and full-year revenue of $7.3–7.5 billion with non-GAAP EPS of $5.90–6.04.
1. Q1 Financial Results
Agilent reported first-quarter fiscal 2026 non-GAAP EPS of $1.36, missing estimates by 0.52%, and delivered revenue of $1.8 billion, up 7% year over year and 4.4% on a core basis, surpassing projections by 0.27%.
2. Segment Performance
The Life Sciences and Diagnostics group generated $679 million (+5% reported, +3% core), CrossLab posted $758 million (+9% reported, +6% core) and Applied Markets produced $361 million (+7% reported, +4% core), accounting for 37.8%, 42.2% and 20.1% of total revenues respectively.
3. Margin and Expense Trends
Gross margins contracted across segments—LDG down 230 bps to 50.5%, CrossLab down 90 bps to 55.2% and Applied Markets down 70 bps to 56.5%—while non-GAAP operating margin narrowed 50 bps to 24.6%. R&D expenses rose 4.5% to $117 million and SG&A increased 5.2% to $406 million.
4. Outlook and Guidance
For Q2, Agilent expects revenue of $1.79–1.82 billion, up 7–9% on a reported basis and 4–5.5% core, with non-GAAP EPS of $1.39–1.42. Full-year guidance targets $7.3–7.5 billion in revenue (5.5–7.5% growth) and non-GAAP EPS of $5.90–6.04.